Synergistic induction of apoptosis by combination of BTK and dual mTORC1/2 inhibitors in diffuse large B cell lymphoma

被引：46

作者：

Ezell, Scott A. ^{[1
]}

Mayo, Michele ^{[1
]}

Bihani, Teeru ^{[1
]}

Tepsuporn, Suprawee ^{[1
]}

Wang, Suping ^{[1
]}

Passino, Melissa ^{[1
]}

Grosskurth, Shaun E. ^{[1
]}

Collins, Mike ^{[1
]}

Parmentier, Julie ^{[1
]}

Reimer, Corinne ^{[1
]}

Byth, Kate F. ^{[1
]}

机构：

[1] AstraZeneca R&D Boston, Waltham, MA 02451 USA

来源：

ONCOTARGET | 2014年 / 5卷 / 13期

关键词：

Ibrutinib; BTK; AZD2014; mTOR; DLBCL; FACTOR-KAPPA-B; BRUTONS TYROSINE KINASE; GENE-EXPRESSION; ACTIVATION; PHOSPHORYLATION; SURVIVAL; ASSOCIATION; MUTATIONS; IBRUTINIB; RECEPTOR;

D O I：

10.18632/oncotarget.2071

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Diffuse large B cell lymphoma is generally treated by chemotherapy and there is an unmet medical need for novel targeted therapies or combination therapies. Using in vitro screening, we have identified the combination of ibrutinib, an inhibitor of the tyrosine kinase BTK, and AZD2014, an mTOR catalytic inhibitor, as being highly synergistic in killing ABC-subtype DLBCL cell lines. Simultaneous inhibition of BTK and mTOR causes apoptosis both in vitro and in vivo and results in tumor regression in a xenograft model. We identify two parallel mechanisms that underlie apoptosis in this setting: cooperative inhibition of cap-dependent translation, and the inhibition of an NF-kappa B/IL10/STAT3 autocrine loop. Combined disruption of these pathways is required for apoptosis. These data represent a rational basis for the dual inhibition of BTK and mTOR as a potential treatment for ABC-subtype DLBCL.

引用

页码：4990 / 5001

页数：12

共 39 条

[21] The mTORC1/mTORC2 inhibitor AZD2014 enhances the radiosensitivity of glioblastoma stem-like cells [J].

Kahn, Jenna ;

Hayman, Thomas J. ;

Jamal, Muhammad ;

Rath, Barbara H. ;

Kramp, Tamalee ;

Camphausen, Kevin ;

Tofilon, Philip J. .

NEURO-ONCOLOGY, 2014, 16 (01) :29-37

[22] Cooperative signaling through the signal transducer and activator of transcription 3 and nuclear factor-κB pathways in subtypes of diffuse large B-cell lymphoma [J].

Lam, Lloyd T. ;

Wright, George ;

Davis, R. Eric ;

Lenz, Georg ;

Farinha, Pedro ;

Dang, Lenny ;

Chan, John W. ;

Rosenwald, Andreas ;

Gascoyne, Randy D. ;

Staudt, Louis M. .

BLOOD, 2008, 111 (07) :3701-3713

[23] ACTIVATION OF INTERLEUKIN-6 GENE-EXPRESSION THROUGH THE NF-KAPPA-B TRANSCRIPTION FACTOR [J].

LIBERMANN, TA ;

BALTIMORE, D .

MOLECULAR AND CELLULAR BIOLOGY, 1990, 10 (05) :2327-2334

[24] Phosphorylation of 4E-BP1 is mediated by the p38/MSK1 pathway in response to UVB irradiation [J].

Liu, GM ;

Zhang, YG ;

Bode, AM ;

Ma, WY ;

Dong, ZG .

JOURNAL OF BIOLOGICAL CHEMISTRY, 2002, 277 (11) :8810-8816

[25] Oncogenically active MYD88 mutations in human lymphoma [J].

Ngo, Vu N. ;

Young, Ryan M. ;

Schmitz, Roland ;

Jhavar, Sameer ;

Xiao, Wenming ;

Lim, Kian-Huat ;

Kohlhammer, Holger ;

Xu, Weihong ;

Yang, Yandan ;

Zhao, Hong ;

Shaffer, Arthur L. ;

Romesser, Paul ;

Wright, George ;

Powell, John ;

Rosenwald, Andreas ;

Muller-Hermelink, Hans Konrad ;

Ott, German ;

Gascoyne, Randy D. ;

Connors, Joseph M. ;

Rimsza, Lisa M. ;

Campo, Elias ;

Jaffe, Elaine S. ;

Delabie, Jan ;

Smeland, Erlend B. ;

Fisher, Richard I. ;

Braziel, Rita M. ;

Tubbs, Raymond R. ;

Cook, J. R. ;

Weisenburger, Denny D. ;

Chan, Wing C. ;

Staudt, Louis M. .

NATURE, 2011, 470 (7332) :115-U133

[26] Bruton's tyrosine kinase is required for activation of IκB kinase and nuclear factor κB in response to B cell receptor engagement [J].

Petro, JB ;

Rahman, SMJ ;

Ballard, DW ;

Khan, WN .

JOURNAL OF EXPERIMENTAL MEDICINE, 2000, 191 (10) :1745-1753

[27] Optimization of potent and selective dual mTORC1 and mTORC2 inhibitors: The discovery of AZD8055 and AZD2014 [J].

Pike, Kurt G. ;

Malagu, Karine ;

Hummersone, Marc G. ;

Menear, Keith A. ;

Duggan, Heather M. E. ;

Gomez, Sylvie ;

Martin, Niall M. B. ;

Ruston, Linette ;

Pass, Sarah L. ;

Pass, Martin .

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2013, 23 (05) :1212-1216

[28] Association between LRRK2 and 4E-BP1 protein levels in normal and malignant cells [J].

Pons, Berta ;

Armengol, Gemma ;

Livingstone, Mark ;

Lopez, Laura ;

Coch, Laura ;

Sonenberg, Nahum ;

Ramon y Cajal, Santiago .

ONCOLOGY REPORTS, 2012, 27 (01) :225-231

[29] Pharmacological and genomic profiling identifies NF-κB-targeted treatment strategies for mantle cell lymphoma [J].

Rahal, Rami ;

Frick, Mareike ;

Romero, Rodrigo ;

Korn, Joshua M. ;

Kridel, Robert ;

Chan, Fong Chun ;

Meissner, Barbara ;

Bhang, Hyo-eun ;

Ruddy, Dave ;

Kauffmann, Audrey ;

Farsidjani, Ali ;

Derti, Adnan ;

Rakiec, Daniel ;

Naylor, Tara ;

Pfister, Estelle ;

Kovats, Steve ;

Kim, Sunkyu ;

Dietze, Kerstin ;

Doerken, Bernd ;

Steidl, Christian ;

Tzankov, Alexandar ;

Hummel, Michael ;

Monahan, John ;

Morrissey, Michael P. ;

Fritsch, Christine ;

Sellers, William R. ;

Cooke, Vesselina G. ;

Gascoyne, Randy D. ;

Lenz, Georg ;

Stegmeier, Frank .

NATURE MEDICINE, 2014, 20 (01) :87-+

[30] Diffuse large B cell lymphoma: molecular targeted therapy [J].

Roschewski, Mark ;

Dunleavy, Kieron ;

Wilson, Wyndham H. .

INTERNATIONAL JOURNAL OF HEMATOLOGY, 2012, 96 (05) :552-561

← 1 2 3 4 →